Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | DPP4 | P27487 | 1/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
| ▸ | PPP5C | P53041 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14670927 | 0.86 | EPHX2 (0.37) | EPHX2ALDH1A1DPP4SMN1; SMN2 | |
| SCHEMBL31619635 | 0.81 | MAPK1 (0.32) | ALDH1A1TSHRGAASMN1; SMN2 | |
| SCHEMBL7700042 | 0.80 | EPHX2 (0.39) | EPHX2ALDH1A1ATMTSHRTDP1 | |
| SCHEMBL15259142 | 0.79 | EPHX2 (0.39) | EPHX2ALDH1A1ATMTSHRTDP1 | |
| SCHEMBL15318695 | 0.79 | EPHX2 (0.39) | EPHX2ALDH1A1ATMTSHRTDP1 | |
| SCHEMBL9914600 | 0.78 | EPHX2 (0.38) | EPHX2ALDH1A1ATMTSHRTDP1 | |
| SCHEMBL10039979 | 0.78 | EPHX2 (0.38) | EPHX2ALDH1A1ATMTSHRTDP1 | |
| SCHEMBL13525934 | 0.78 | EPHX2 (0.38) | EPHX2ALDH1A1ATMTSHRTDP1 | |
| SCHEMBL19363858 | 0.77 | EPHX2 (0.37) | EPHX2ALDH1A1ATMTSHRTDP1 | |
| SCHEMBL15928428 | 0.77 | EPHX2 (0.37) | EPHX2ALDH1A1ATMTSHRTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170326149-A1 | HYDROXYL PURINE COMPOUNDS AND APPLICATIONS THEREOF | GUANGDONG ZHONGSHENG PHARMACEUTICAL CO., LTD (CN) | 2017-11-16 | — | — | US | disclosed |
| EP-3205652-A1 | HYDROXYL PURINE COMPOUNDS AND APPLICATIONS THEREOF | Medshine Discovery Inc. (CN) | 2017-08-16 | — | — | EP | disclosed |
| WO-2017071606-A1 | MEDICAL USE OF HYDROXYL PURINE COMPOUND | 南京明德新药研发股份有限公司 | 2017-05-04 | — | — | WO | disclosed |
| WO-2016054971-A1 | HYDROXYL PURINE COMPOUNDS AND APPLICATIONS THEREOF | 南京明德新药研发股份有限公司 | 2016-04-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170326149-A1 | HYDROXYL PURINE COMPOUNDS AND APPLICATIONS THEREOF | PNP, PDE2A, PDE7A | EPHX2 341/4885ALDH1A1 265/4885DPP4 672/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.